

Therapeutic Anticoagulation with Heparin in Noncritic

New England Journal of Medicine

385, 790-802

DOI: [10.1056/nejmoa2105911](https://doi.org/10.1056/nejmoa2105911)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study. <i>Cardiovascular Research</i> , 2021, 117, 2807-2820.	1.8	21
2	Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study. <i>JMIR Medical Informatics</i> , 2021, 9, e30743.	1.3	3
3	Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1533-1545.	1.9	21
4	Anticoagulation in COVID-19: reaction to the ACTION trial. <i>Lancet, The</i> , 2021, 397, 2226-2228.	6.3	14
5	Pulmonary Thrombosis and Thromboembolism in COVID-19. <i>Chest</i> , 2021, 160, 1471-1480.	0.4	92
7	Heparin â€“ Messias or Verschlimmbesserung?. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2373-2382.	1.9	8
8	The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study. <i>Viruses</i> , 2021, 13, 1720.	1.5	9
10	Thromboembolism and Bleeding in COVID-19. <i>J</i> , 2021, 4, 476-485.	0.6	1
11	Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 1387-1395.	5.2	259
12	The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 1-9.	2.3	31
13	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3080-3089.	1.9	13
14	Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2022, 28, 93-112.	0.7	15
15	Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, , 1.	1.0	5
16	Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an â€“oldâ€™ strategy. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000867.	1.2	17
17	Cardiovascular implications of the COVID-19 pandemic. <i>Journal of Cardiology</i> , 2022, 79, 460-467.	0.8	7
18	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 677-686.	1.4	45
19	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Public Health</i> , 2021, 9, 729559.	1.3	27
20	Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis. <i>Blood Advances</i> , 2021, 5, 4521-4534.	2.5	19

#	ARTICLE	IF	CITATIONS
21	A hitchhiker's guide through the COVID-19 galaxy. <i>Clinical Immunology</i> , 2021, 232, 108849.	1.4	3
22	Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19. <i>Chest</i> , 2022, 161, 710-727.	0.4	36
23	Emerging and Established Histological Techniques for the Analysis of Thrombosis in COVID-19 Lungs. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 745906.	1.1	1
24	The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases. <i>Viruses</i> , 2021, 13, 1904.	1.5	24
26	Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study. <i>Anesthesiology</i> , 2021, 135, 1076-1090.	1.3	3
27	Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. <i>EClinicalMedicine</i> , 2021, 41, 101139.	3.2	19
28	Anticoagulation is the answer in treating noncritical COVID-19 patients. <i>Open Medicine (Poland)</i> , 2021, 16, 1486-1492.	0.6	4
29	Comprehensive Review of Cardiovascular Complications of Coronavirus Disease 2019 and Beneficial Treatments. <i>Cardiology in Review</i> , 2022, 30, 145-157.	0.6	11
30	Antithrombotic Therapy for Outpatients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1685.	3.8	3
32	Impact of major bleeding and thrombosis on 180-day survival in patients with severe COVID-19 supported with veno-venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study. <i>British Journal of Haematology</i> , 2022, 196, 566-576.	1.2	27
33	Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1690.	3.8	169
34	Stroke Prevention After Cryptogenic Stroke. <i>Current Cardiology Reports</i> , 2021, 23, 174.	1.3	9
35	Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 295-299.	1.8	40
36	Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. <i>BMJ, The</i> , 2021, 375, n2400.	3.0	250
37	The Value of Thromboelastography (TEG) in COVID-19 Critical Illness as Illustrated by a Case Series. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 2536-2543.	0.6	4
38	Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry. <i>Heart</i> , 2022, 108, 130-136.	1.2	49
39	What went wrong: A reckoning of Canada's contributions to evidence-based medicine through clinical trials during the COVID-19 pandemic. <i>Jammi</i> , 2021, 6, 241-244.	0.3	2
40	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	1.2	42

#	ARTICLE	IF	CITATIONS
41	Complications of Critical COVID-19. Chest, 2022, 161, 989-998.	0.4	14
42	Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. JAMA Internal Medicine, 2021, 181, 1612.	2.6	326
43	<scp>COVID</scp>â€19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1806-1818.	2.9	32
44	Age-adjusted D-dimer cutoffs to guide anticoagulation in COVID-19 â€ Authors' reply. Lancet, The, 2021, 398, 1304.	6.3	0
45	Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism. Frontiers in Cardiovascular Medicine, 2021, 8, 711923.	1.1	2
47	Anticoagulant Therapy in Patients Hospitalized With COVID-19. JAMA Internal Medicine, 2021, 181, 1621.	2.6	11
48	Role of neutrophils, platelets, and extracellular vesicles and their interactions in COVIDâ€19â€associated thrombopathy. Journal of Thrombosis and Haemostasis, 2022, 20, 17-31.	1.9	45
49	Glucocorticoid Dose in COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1801.	3.8	8
50	Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study. International Journal of Cardiology, 2021, 344, 240-245.	0.8	17
51	PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19. Viruses, 2021, 13, 2128.	1.5	4
52	Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study. Open Heart, 2021, 8, e001785.	0.9	18
53	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1703.	3.8	186
54	Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study. Thrombosis Research, 2021, 208, 35-38.	0.8	1
55	Risk of symptomatic venous thromboembolism in mild and moderate COVID-19: A comparison of two prospective European cohorts. Thrombosis Research, 2021, 208, 4-10.	0.8	14
56	SOFA Score as a Reliable Tool to Detect High Risk for Venous Thrombosis in Patients With Critical Stage SARS-CoV-2. Frontiers in Cardiovascular Medicine, 2021, 8, 729298.	1.1	3
57	Caring for Hospitalized COVID-19 Patients: From Hypes and Hopes to Doing the Simple Things First. American Journal of Tropical Medicine and Hygiene, 2021, , .	0.6	1
58	Significance of MPV, RDW and PDW with the Severity and Mortality of COVID-19 and Effects of Acetylsalicylic Acid Use. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110488.	0.7	9
60	Dilemma of Anticoagulation Therapy in Mild or Asymptomatic COVID-19 Cases. Cureus, 2021, 13, e19291.	0.2	2

#	ARTICLE	IF	CITATIONS
61	Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. <i>BMJ, The</i> , 2021, 375, e068060.	3.0	52
62	Host-modifying drugs against COVID-19: some successes, but not yet the breakthrough. <i>Environmental Microbiology</i> , 2021, 23, 7257-7270.	1.8	0
63	Clinical Practice in COVID-19: the most frequently asked questions to Infectious Diseases Specialists. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101648.	0.3	1
64	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12081.	1.8	21
65	COVID-19 associated coagulopathy: Mechanisms and host-directed treatment. <i>American Journal of the Medical Sciences</i> , 2022, 363, 465-475.	0.4	16
66	COVID-19 critical illness in pregnancy. <i>Obstetric Medicine</i> , 2022, 15, 220-224.	0.5	3
67	Clinical practice guideline: Recommendations on the in-hospital treatment of patients with COVID-19. <i>Deutsches A&#x0308;rztblatt International</i> , 2021, , .	0.6	15
68	A Population-Based Registry Analysis on Hospitalized COVID-19 Patients with Previous Cardiovascular Disease: Clinical Profile, Treatment, and Predictors of Death. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 167.	0.8	2
69	Learning in times of stress: Lessons from COVID-19 that will last throughout this century. <i>European Journal of Internal Medicine</i> , 2021, , .	1.0	1
70	Mortality Reduction Associated with Coexistent Antithrombotic Use in Nursing Home Residents with COVID-19. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 440-441.	1.2	1
71	Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 767074.	1.1	20
72	Therapeutic Anticoagulation with Heparin in Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 2013-2014.	13.9	1
73	ESCMID COVID-19 living guidelines: drug treatment and clinical management. <i>Clinical Microbiology and Infection</i> , 2022, 28, 222-238.	2.8	103
74	Immune-Mediated Glycocalyx Remodeling in Hospitalized COVID-19 Patients. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 307-313.	1.3	12
75	Ethical challenges of prospective clinical trials during the COVID-19 pandemic. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 549-554.	2.0	1
76	Incidence and effects of deep vein thrombosis on the outcome of patients with coronavirus disease 2019 infection. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2022, 10, 803-810.	0.9	5
77	Predictors and outcomes of respiratory failure among lung transplant patients with COVID-19. <i>Clinical Transplantation</i> , 2022, 36, e14540.	0.8	4
78	Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis. <i>Thrombosis Journal</i> , 2021, 19, 91.	0.9	12

#	ARTICLE	IF	CITATIONS
79	Therapeutic-dose heparin should integrate the standard of care of moderately ill patients with COVID-19 admitted to hospital. <i>European Heart Journal</i> , 2022, 43, 365-366.	1.0	0
80	Novel Coronavirus Infection (COVID-19) Related Thrombotic and Bleeding Complications in Critically Ill Patients: Experience from an Academic Medical Center. <i>Journal of Clinical Medicine</i> , 2021, 10, 5652.	1.0	2
81	The relationship between COVID-19 infection and intracranial hemorrhage: A systematic review. <i>Brain Hemorrhages</i> , 2021, 2, 141-150.	0.4	26
82	The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 257-265.	0.8	18
83	Thrombosis and Bleeding After Implementation of an Intermediate-Dose Prophylactic Anticoagulation Protocol in ICU Patients With COVID-19: A Multicenter Screening Study. <i>Journal of Intensive Care Medicine</i> , 2021, , 088506662110519.	1.3	3
84	Validation of a Prognostic Score to Identify Hospitalized Patients with COVID-19 at Increased Risk for Bleeding. <i>Viruses</i> , 2021, 13, 2278.	1.5	10
85	Anticoagulant therapy for COVID-19: What we have learned and what are the unanswered questions?. <i>European Journal of Internal Medicine</i> , 2022, 96, 13-16.	1.0	9
86	2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2021, 37, 1389-1426.	0.5	38
87	Daily Monitoring of D-Dimer Allows Outcomes Prediction in COVID-19. <i>TH Open</i> , 2022, 06, e21-e25.	0.7	9
88	Coagulopathies in Intensive Care Medicine: Balancing Act between Thrombosis and Bleeding. <i>Journal of Clinical Medicine</i> , 2021, 10, 5369.	1.0	7
89	2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. <i>Thrombosis and Haemostasis</i> , 2022, 122, 020-047.	1.8	192
90	High versus Standard Intensity of Thromboprophylaxis in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 5549.	1.0	13
91	Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 214-220.	5.2	37
92	Intubation to Nowhere in COVID-19. <i>Mayo Clinic Proceedings</i> , 2022, 97, 4-6.	1.4	2
93	Treatments for COVID-19: Lessons from 2020 and new therapeutic options. <i>Current Opinion in Pharmacology</i> , 2022, 62, 43-59.	1.7	23
95	TEGÂ®, Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 5381.	1.0	30
96	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2022, 399, 143-151.	6.3	199
97	Global lessons learned from COVID-19 mass casualty incidents. <i>British Journal of Anaesthesia</i> , 2022, 128, e97-e100.	1.5	7

#	ARTICLE	IF	CITATIONS
98	Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients. <i>International Journal of Cardiology</i> , 2022, 349, 157-165.	0.8	10
99	Anticoagulant Treatment Regimens in Patients With Covid-19: A Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 614-623.	2.3	20
100	Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. <i>American Heart Journal</i> , 2022, 246, 136-143.	1.2	8
101	Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare. <i>Clinical Ophthalmology</i> , 2022, Volume 16, 1-13.	0.9	16
102	From the Heart to the Brain: Building Bridges to a Better Future. <i>Stroke</i> , 2022, , STROKEAHA121036763.	1.0	0
103	Interpreting recent clinical studies for COVID-19: A continual process with more new data. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, 41, 101016.	0.6	3
104	Use and misuse of biomarkers and the role of D-dimer and C-reactive protein in the management of COVID-19: A post-hoc analysis of a prospective cohort study. <i>Clinics</i> , 2021, 76, e3547.	0.6	13
105	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. <i>Nature Reviews Cardiology</i> , 2022, 19, 475-495.	6.1	180
106	Efficacy and safety of therapeutic vs. prophylactic bempiparin in noncritically ill patients with COVID-19 pneumonia. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	3
107	Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy. <i>Vaccines</i> , 2022, 10, 192.	2.1	20
108	Clinico-histopathologic and single-nuclei RNA-sequencing insights into cardiac injury and microthrombi in critical COVID-19. <i>JCI Insight</i> , 2022, 7, .	2.3	14
109	Treatment of MIS-C in Children and Adolescents. <i>Current Pediatrics Reports</i> , 2022, 10, 1-10.	1.7	41
110	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 227.	3.8	89
111	COVID-19: Les thérapeutiques. , 2022, 1, 13-13.		0
112	Serial Thromboelastography and the Development of Venous Thromboembolism in Critically Ill Patients With COVID-19. , 2022, 4, e0618.		5
113	The Central Role of Extracellular Vesicles in the Mechanisms of Thrombosis in COVID-19 Patients With Cancer and Therapeutic Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 792335.	1.8	3
114	Anticoagulation in COVID-19. <i>Lancet, The</i> , 2022, 399, 5-7.	6.3	18
115	Thromboelastography determined dynamics of blood coagulation and its correlation with complications and outcomes in patients with coronavirus disease 2019. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12645.	1.0	5

#	ARTICLE	IF	CITATIONS
116	A proteomic survival predictor for COVID-19 patients in intensive care. , 2022, 1, e0000007.		28
117	Intracranial Hemorrhages on Extracorporeal Membrane Oxygenation. Critical Care Medicine, 2022, Publish Ahead of Print, .	0.4	33
118	Circulating Microparticles in the Pathogenesis and Early Anticoagulation of Thrombosis in COVID-19 With Kidney Injury. Frontiers in Cell and Developmental Biology, 2021, 9, 784505.	1.8	5
119	COVID-19 and Elevated D-Dimer: A Tale of Caution. Journal of General Internal Medicine, 2022, 37, 1304-1305.	1.3	1
120	COVID-19 in the Critically Ill Pregnant Patient. Critical Care Clinics, 2022, , .	1.0	5
121	Platelets and Antiplatelet Medication in COVID-19-Related Thrombotic Complications. Frontiers in Cardiovascular Medicine, 2021, 8, 802566.	1.1	7
122	Methylprednisolone, venous thromboembolism, and association with heparin to 30Âdays in hospital survival in severe Covid-19 pneumonia. BMC Pulmonary Medicine, 2022, 22, 6.	0.8	5
123	COVID-19 and Acute Kidney Injury. Critical Care Clinics, 2022, 38, 473-489.	1.0	21
124	Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet, The, 2022, 399, 50-59.	6.3	172
125	Fibrinolytics as an ARDS Salvage Option. Chest, 2022, 161, 595-596.	0.4	0
126	Anticoagulation Prior to COVID-19 Infection Has No Impact on 6 Months Mortality: A Propensity Scoreâ€“Matched Cohort Study. Journal of Clinical Medicine, 2022, 11, 352.	1.0	10
127	Antiplatelet Therapy in Patients With COVID-19â€”More Is Less?. JAMA - Journal of the American Medical Association, 2022, 327, 223.	3.8	10
128	Arrhythmias in the COVID-19 patient. Heart Rhythm O2, 2022, 3, 8-14.	0.6	12
129	A guide to immunotherapy for COVID-19. Nature Medicine, 2022, 28, 39-50.	15.2	206
131	Effects of dalteparin on antiâ€“Xa activities cannot be predicted in critically ill COVIDâ€“19 patients. British Journal of Clinical Pharmacology, 2021, , .	1.1	4
132	Thromboprophylaxis for COVID-19-related coagulopathy: what next?. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	1.4	1
133	Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, E15-E17.	1.4	15
134	Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial. American Journal of Tropical Medicine and Hygiene, 2022, 106, 389-393.	0.6	1

#	ARTICLE	IF	CITATIONS
135	Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1008-1014.	1.9	18
136	Thrombosis and fibrosis: mutually inclusive targets to combat in COVID-19. <i>Future Science OA</i> , 2022, 8, FSO777.	0.9	1
137	Dexamethasone Improves Cardiovascular Outcomes in Critically Ill COVID-19, a Real World Scenario Multicenter Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 808221.	1.2	6
138	Thromboembolic complications during and after hospitalization for COVID-19: Incidence, risk factors and thromboprophylaxis. <i>Thrombosis Update</i> , 2022, 6, 100096.	0.4	2
139	Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2022, 5, 100101.	0.6	8
140	Anticoagulation as a therapeutic strategy for hospitalised patients with COVID-19. <i>Thrombosis Update</i> , 2022, 6, 100097.	0.4	1
141	Multi-organ point-of-care ultrasound for detection of pulmonary embolism in critically ill COVID-19 patients – A diagnostic accuracy study. <i>Journal of Critical Care</i> , 2022, 69, 153992.	1.0	5
142	Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. <i>European Heart Journal</i> , 2022, 43, 1157-1172.	1.0	297
143	Rectus Sheath Hematoma in COVID-19 Patients as a Mortal Complication: A Retrospective Report. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-7.	0.8	8
144	COVID-19 Coagulopathy: From Pathogenesis to Treatment. <i>Acta Haematologica</i> , 2022, 145, 282-296.	0.7	19
146	Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. <i>Journal of Clinical Medicine</i> , 2022, 11, 860.	1.0	41
147	Thrombosis pathways in COVID-19 versus influenza-associated ARDS: a targeted proteomics approach. <i>Journal of Thrombosis and Haemostasis</i> , 2022, , .	1.9	4
148	Comparison between standard Vs. Escalated dose venous thromboembolism (VTE) prophylaxis in critically ill patients with COVID-19: A two centers, observational study. <i>Saudi Pharmaceutical Journal</i> , 2022, 30, 398-406.	1.2	5
149	Thromboprophylaxis in Patients With COVID-19. <i>Chest</i> , 2022, 162, 213-225.	0.4	58
150	Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac043.	0.4	4
151	Regional citrate and systemic heparin are adequate to maintain filter half-life for COVID-19 patients on continuous renal replacement therapy. <i>Seminars in Dialysis</i> , 2022, , .	0.7	2
152	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. <i>Arthritis and Rheumatology</i> , 2022, 74, .	2.9	146
153	Use of Systemic Anticoagulation in COVID-19: Delving Beyond Theoretical Hypothesis. <i>Cureus</i> , 2022, 14, e22061.	0.2	0

#	ARTICLE	IF	CITATIONS
154	The association between anticoagulation and adverse outcomes after a positive SARS-CoV-2 test among older outpatients: A population-based cohort study. <i>Thrombosis Research</i> , 2022, 211, 114-122.	0.8	5
155	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. <i>Current Infectious Disease Reports</i> , 2021, 23, 28.	1.3	5
156	Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab588.	0.4	7
157	Alveolar, Endothelial, and Organ Injury Marker Dynamics in Severe COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 507-519.	2.5	56
158	The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. <i>European Respiratory Review</i> , 2021, 30, 210171.	3.0	20
159	Heparin and SARS-CoV-2: Multiple Pathophysiological Links. <i>Viruses</i> , 2021, 13, 2486.	1.5	10
160	Heparin-induced thrombocytopenia in COVID-19: A systematic review. <i>Anesthesia: Essays and Researches</i> , 2021, 15, 341.	0.2	4
161	Active site prediction of phosphorylated SARS-CoV-2 N-Protein using molecular simulation. <i>Informatics in Medicine Unlocked</i> , 2022, 29, 100889.	1.9	1
162	Anticoagulants and corticosteroids in COVID-19: What do we know so far?. <i>Srpski Medicinski Åasopis Lekarske Komore</i> , 2022, 3, 62-74.	0.1	1
163	Report of Low Incidence of Thrombosis with Early Prophylaxis in Hospitalized Patients with COVID-19 from Two Saudi Tertiary Centers. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210862.	0.7	2
164	âœMATH+âœMulti-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale. <i>Journal of Clinical Medicine Research</i> , 2022, 14, 53-79.	0.6	4
165	A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. <i>Biochemical Journal</i> , 2022, 479, 537-559.	1.7	126
166	Contribution of the elevated thrombosis risk of males to the excess male mortality observed in COVID-19: an observational study. <i>BMJ Open</i> , 2022, 12, e051624.	0.8	4
167	MULTICENTER STudy of tissue plasminogen activator (alteplase) use in COVIDâ€19 severe respiratory failure (MUST COVID): Aretrospective cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12669.	1.0	6
168	COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. <i>Kidney International</i> , 2022, 101, 883-894.	2.6	82
171	COVIDâ€19 and venous thromboembolism: A narrative review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12666.	1.0	16
172	COVID-19 ARDS: One Pathogen, Multiple Phenotypes. <i>Critical Care Clinics</i> , 2022, , .	1.0	6
173	European Society of Cardiology Highlights: Late-breaking Trials âœ COVID-19. <i>European Cardiology Review</i> , 2022, 17, e04.	0.7	0

#	ARTICLE	IF	CITATIONS
174	Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study. <i>Antibiotics</i> , 2022, 11, 241.	1.5	4
175	Left Ventricular Thrombus of Unknown Etiology in a Patient With COVID-19 Disease With No Significant Medical History. <i>Cardiovascular Revascularization Medicine</i> , 2022, 40, 329-331.	0.3	2
176	Anticoagulation Strategies in Critically Ill Patients With SARS-CoV-2 Infection: The Role of Direct Thrombin Inhibitors. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 2961-2967.	0.6	4
177	The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. <i>CJC Open</i> , 2022, 4, 568-576.	0.7	4
178	The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 807934.	2.2	24
179	Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation. <i>Viruses</i> , 2022, 14, 737.	1.5	7
180	Low versus high dose anticoagulation in patients with Coronavirus 2019 pneumonia at the time of admission to critical care units: A multicenter retrospective cohort study in the Beaumont healthcare system. <i>PLoS ONE</i> , 2022, 17, e0265966.	1.1	2
181	How far are we from predicting multi-drug interactions during treatment for COVID-19 infection?. <i>British Journal of Pharmacology</i> , 2022, 179, 3831-3838.	2.7	1
182	Full <i>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis. <i>Haematologica</i> , 2022, 107, 1933-1939.	1.7	5
183	COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No. <i>Chest</i> , 2022, 161, 1448-1451.	0.4	6
185	Impact of Thromboprophylaxis Intensity on Patients's™ Mortality Among Hospitalized Patients with COVID-19: A Propensity-Score Matched Study. <i>Clinical Epidemiology</i> , 2022, Volume 14, 361-368.	1.5	1
186	Clinical Evidence Generation During a Pandemic. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 151-156.	1.0	2
187	Cardiovascular Dysfunction in COVID-19: Association Between Endothelial Cell Injury and Lactate. <i>Frontiers in Immunology</i> , 2022, 13, 868679.	2.2	7
188	Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3577-3599.	1.1	7
189	Successful treatment of intracardiac thrombosis in the presence of fulminant myocarditis requiring ECMO associated with COVID-19. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 849-851.	0.3	1
191	Immunothrombosis and the molecular control of tissue factor by pyroptosis: prospects for new anticoagulants. <i>Biochemical Journal</i> , 2022, 479, 731-750.	1.7	9
192	What Are Adaptive Platform Clinical Trials and What Role May They Have in Cardiovascular Medicine?. <i>Circulation</i> , 2022, 145, 629-632.	1.6	19
193	Thrombosis and coagulopathy in COVID-19 patients receiving ECMO: a narrative review of current literature. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 3312-3317.	0.6	6

#	ARTICLE	IF	CITATIONS
194	Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19. <i>IScience</i> , 2022, 25, 103971.	1.9	7
195	Anticoagulation in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2022, 79, 917-928.	1.2	35
196	Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3338.	1.8	11
197	One Year Prevalence of Venous Thromboembolism in Hospitalized COVID-19 Patients in France: Patients' Characteristics, Time Trends, and Outcomes. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1532-1541.	1.8	5
198	Whole-genome sequencing reveals host factors underlying critical COVID-19. <i>Nature</i> , 2022, 607, 97-103.	13.7	174
199	POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes. <i>Chest</i> , 2022, 161, 1446-1448.	0.4	8
200	The Future of Critical Care: Optimizing Technologies and a Learning Healthcare System to Potentiate a More Humanistic Approach to Critical Care. , 2022, 4, e0659.		11
201	Coreceptor functions of cell surface heparan sulfate proteoglycans. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 322, C896-C912.	2.1	20
202	Effect of plasma exchange on COVID-19 associated excess of von Willebrand factor and inflammation in critically ill patients. <i>Scientific Reports</i> , 2022, 12, 4801.	1.6	10
203	Prophylactic anticoagulation with low molecular weight heparin in COVID-19: cohort studies in Denmark and Sweden. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1291.e1-1291.e5.	2.8	3
205	In Situ Pulmonary Thrombolysis and Perfusion Lung Angiography in Severe COVID-19 Respiratory Failure. , 2022, 4, e0670.		0
206	Efficacy of different anticoagulant doses for patients with COVID-19: a systematic review and network meta-analysis. <i>Infection</i> , 2022, 50, 1453-1463.	2.3	4
207	Rebuttal From Dr David Jimenez et Al. <i>Chest</i> , 2022, 161, 1453-1455.	0.4	0
208	Role of Acute Thrombosis in COVID-19. <i>Critical Care Clinics</i> , 2022, , .	1.0	3
210	Tools to Reduce Low-Value Care: Lessons From COVID-19 Pandemic; Comment on "Key Factors That Promote Low-Value Care: Views of Experts From the United States, Canada, and the Netherlands". <i>International Journal of Health Policy and Management</i> , 2022, , .	0.5	0
211	Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis. <i>Frontiers in Microbiology</i> , 2022, 13, 860931.	1.5	15
212	Shining a light on platelet activation in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, , .	1.9	3
213	Naloxegol to Prevent Constipation in ICU Adults Receiving Opioids: A Randomized Double-Blind Placebo-Controlled Pilot Trial. <i>Critical Care Research and Practice</i> , 2022, 2022, 1-10.	0.4	1

#	ARTICLE	IF	CITATIONS
214	Factores de riesgo de mortalidad en pacientes con infección por SARS-CoV-2 y fibrilación auricular: datos del registro SEMI-COVID-19. Medicina Clínica, 2022, 159, 457-464.	0.3	4
215	Extracardiac Prothrombotic Effects of COVID-19. Cardiology Clinics, 2022, , .	0.9	2
216	D-Dimer Values and Venous Thromboembolism in Patients With COVID-19 in Japan From the CLOT-COVID Study. Circulation Reports, 2022, , .	0.4	4
218	Thromboprophylaxis in COVID-19: Weight and severity adjusted intensified dosing. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12683.	1.0	4
219	Challenging management dogma where evidence is non-existent, weak or outdated. Intensive Care Medicine, 2022, 48, 548-558.	3.9	10
220	D-dimer and CoV-2 spike-immune complexes contribute to the production of PGE2 and proinflammatory cytokines in monocytes. PLoS Pathogens, 2022, 18, e1010468.	2.1	7
221	COVID-19 therapeutics: Challenges and directions for the future. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2119893119.	3.3	92
222	Thromboinflammation and Antithrombotics in COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1234.	3.8	9
223	Persistent Lung Injury and Prothrombotic State in Long COVID. Frontiers in Immunology, 2022, 13, 862522.	2.2	15
224	Association between pre-admission anticoagulation and in-hospital death, venous thromboembolism, and major bleeding among hospitalized COVID-19 patients in Japan. Pharmacoepidemiology and Drug Safety, 2022, 31, 680-688.	0.9	5
225	Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study. Viruses, 2022, 14, 767.	1.5	4
226	The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study. Journal of Cardiology, 2022, 80, 285-291.	0.8	18
227	Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1247.	3.8	83
228	Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study. Respiratory Medicine and Research, 2022, 81, 100903.	0.4	3
229	Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study. Thrombosis Research, 2022, 213, 173-178.	0.8	12
230	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management. American Journal of Emergency Medicine, 2022, 56, 158-170.	0.7	13
231	(Acute pulmonary embolism). Cor Et Vasa, 2021, 63, 675-682.	0.1	0
233	Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: a propensity-matched analysis of in-hospital outcomes. Journal of Cardiovascular Medicine, 2022, 23, 264-271.	0.6	12

#	ARTICLE	IF	CITATIONS
235	Nebulized enriched heparin to treat no critical patients with Sars-Cov-2. <i>Medicine (United States)</i> , 2021, 100, e28288.	0.4	3
236	Comparison of Higher-Than-Standard to D-Dimer Driven Thromboprophylaxis in Hospitalized Patients With COVID-19. <i>Hospital Pharmacy</i> , 0, , 001857872110664.	0.4	1
237	The Pathobiological Basis for Thrombotic Complications in COVID-19: a Review of the Literature. <i>Current Pathobiology Reports</i> , 2021, 9, 107-117.	1.6	6
238	Randomized trials of therapeutic heparin for COVID-19: A meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12638.	1.0	39
239	Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 5815.	1.0	6
240	Risk Factors for Venous Thromboembolism in Severe COVID-19: A Study-Level Meta-Analysis of 21 Studies. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12944.	1.2	19
241	COVID-19 and thrombosis: searching for evidence. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 621-627.	0.9	12
242	Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The COVID-19 Randomized Trial. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13735.	1.7	31
243	Thrombotic and Clinical Outcomes in Patients with Hematologic Malignancy and COVID-19. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	2
244	MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 710-717.	0.9	2
245	Clinical features and acute management of COVID-19 in adults. , 2021, , 101-123.		2
246	The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e153-e158.	4.6	22
248	Safety and Efficacy of Intermediate- and Therapeutic-Dose Anticoagulation for Hospitalised Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 57.	1.0	11
249	COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103529.	2.0	22
250	Lessening Organ Dysfunction With Vitamin C (LOVIT) Trial: Statistical Analysis Plan. <i>JMIR Research Protocols</i> , 2022, 11, e36261.	0.5	3
251	First do no harm. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12694.	1.0	2
252	Anticoagulation as secondary prevention of massive lung thromboses in hospitalized patients with COVID-19. <i>European Journal of Internal Medicine</i> , 2022, 100, 21-24.	1.0	7
253	Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19. <i>Journal of Virology</i> , 2022, 96, e0005722.	1.5	14

#	ARTICLE	IF	CITATIONS
254	Preinfection Anticoagulation/Antiplatelet Therapy Does Not Influence the Outcome of COVID-19 Disease in Hospitalized Patients. <i>American Journal of Therapeutics</i> , 2022, Publish Ahead of Print, .	0.5	0
255	New Insights in the Occurrence of Venous Thromboembolism in Critically Ill Patients with COVID-19—A Large Postmortem and Clinical Analysis. <i>Viruses</i> , 2022, 14, 811.	1.5	3
256	COVID-19 and Cardiac Arrhythmias: a Contemporary Review. Current Treatment Options in Cardiovascular Medicine, 2022, 24, 87-107.	0.4	15
257	COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells. <i>Seminars in Immunopathology</i> , 2022, 44, 375-390.	2.8	15
258	Acute Arterial Occlusions in COVID-19 Times: A Comparison Study Among Patients with Acute Limb Ischemia With or Without COVID-19 Infection. <i>Annals of Vascular Surgery</i> , 2022, 83, 80-86.	0.4	3
259	Physiology Is Vital to Precision Medicine in Acute Respiratory Distress Syndrome and Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 14-16.	2.5	10
260	Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022). <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 399-419.	1.0	1
261	To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 062-072.	1.5	13
262	Automated measurement of coagulation and fibrinolytic activation markers: Outcomes in coronavirus disease 2019 (<scp>COVID</scp>â€19) patients. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 817-822.	0.7	3
263	Epidemiology and Management of STâ€Segmentâ€Elevation Myocardial Infarction in Patients With COVIDâ€19: A Report From the American Heart Association COVIDâ€19 Cardiovascular Disease Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e024451.	1.6	6
264	Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 1238-1249.	1.3	3
265	Clinical features of thrombosis and bleeding in COVID-19. <i>Blood</i> , 2022, 140, 184-195.	0.6	29
267	Thromboembolic Events in Deceased Patients with Proven SARS-CoV-2 Infection: Frequency, Characteristics and Risk Factors. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
268	The Association between the Development of Thrombosis and Worsening of Disease Severity in Patients with Moderate COVID-19 on Admission: From the CLOT-COVID Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
269	Ischemic Stroke and SARS-CoV-2 Infection: The Bidirectional Pathology and Risk Morbidities. <i>Neurology International</i> , 2022, 14, 391-405.	1.3	25
270	Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset Hypoxemia. <i>Chest</i> , 2022, 162, 804-814.	0.4	10
271	Stroke Treatment in the Era of COVID-19: a Review. <i>Current Treatment Options in Neurology</i> , 2022, 24, 155-171.	0.7	9
272	Use of Anticoagulants in COVID-19: A Review. <i>American Journal of Therapeutics</i> , 2022, 29, e425-e436.	0.5	4

#	ARTICLE	IF	CITATIONS
273	A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2). <i>Frontiers in Medicine</i> , 2022, 9, 785785.	1.2	15
274	COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 573-583.	2.5	16
277	Reflections on defining a standard for computable expression of scientific knowledge: What teach us Yoda can. <i>Learning Health Systems</i> , 0, , .	1.1	0
278	A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	0.8	3
280	Venous thromboembolism in COVID-19 patients and prediction model: a multicenter cohort study. <i>BMC Infectious Diseases</i> , 2022, 22, 462.	1.3	17
281	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. <i>Blood Advances</i> , 2022, 6, 4915-4923.	2.5	42
282	Double Trouble: A Case of Two Simultaneous Thrombotic Events in a Patient With COVID-19. <i>Cureus</i> , 2022, , .	0.2	0
283	Obesity and Its Impact on Adverse In-Hospital Outcomes in Hospitalized Patients With COVID-19. <i>Frontiers in Endocrinology</i> , 2022, 13, 876028.	1.5	11
285	Venous thromboembolism (VTE) prevention and diagnosis in COVID-19: Practice patterns and outcomes at 33 hospitals. <i>PLoS ONE</i> , 2022, 17, e0266944.	1.1	4
286	Anticoagulant Treatment in Severe ARDS COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 2695.	1.0	4
287	Immuno-Thrombotic Complications of COVID-19: Implications for Timing of Surgery and Anticoagulation. <i>Frontiers in Surgery</i> , 2022, 9, .	0.6	23
288	Assessment of Bleeding Risk in Hospitalized COVID-19 Patients: A Tertiary Hospital Experience during the Pandemic in a Predominant Minority Populationâ€”Bleeding Risk Factors in COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 2754.	1.0	2
289	Plasma Proteomics of COVID-19â€™Associated Cardiovascular Complications. <i>JACC Basic To Translational Science</i> , 2022, 7, 425-441.	1.9	17
290	COVID-19 associated rhabdomyolysis leading to major amputation in the absence of macrovascular thrombosis. <i>Annals of Vascular Surgery Brief Reports and Innovations</i> , 2022, 2, 100082.	0.1	2
292	Venous and arterial thrombosis in COVID-19: An updated narrative review. <i>Journal of Infection and Public Health</i> , 2022, 15, 689-702.	1.9	6
293	Comparison of standard prophylactic, intermediate prophylactic and therapeutic anticoagulation in patients with severe COVID-19: protocol for the ANTICOVID multicentre, parallel-group, open-label, randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e059383.	0.8	3
294	Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 730-739.	2.5	10
295	Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 197-210.	1.0	29

#	ARTICLE	IF	CITATIONS
296	Diagnosis and management of covid-19 in pregnancy. <i>BMJ, The</i> , 2022, 377, e069739.	3.0	25
297	Double Jeopardy: Precapillary Pulmonary Hypertension Increases the Risk of Hospitalization and Death from COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, , .	2.5	0
298	Screening the Potential Biomarkers of COVID-19-Related Thrombosis Through Bioinformatics Analysis. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	0
299	Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	18
300	COVID-19 associated coagulopathy and thrombosis in cancer. <i>Thrombosis Research</i> , 2022, 213, S72-S76.	0.8	1
301	Venous Gangrene Associated with COVID-19: Successful Limb Preservation Strategies with Optimal Wound Management. <i>Annals of Vascular Surgery Brief Reports and Innovations</i> , 2022, , 100095.	0.1	0
302	Prophylactic Anticoagulation and Thrombosis in Hospitalized Patients with Clinically Stable COVID-19 at Admission: From the CLOT-COVID Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
303	Thromboprophylaxis and anticoagulation for inpatients with coronavirus disease 2019 in 2022 and beyond. <i>Clinical Microbiology and Infection</i> , 2022, , .	2.8	0
304	D-dimer testing in clinical practice in the era of COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12730.	1.0	9
305	Acute Coronary Syndrome in the COVID-19 Era—Differences and Dilemmas Compared to the Pre-COVID-19 Era. <i>Journal of Clinical Medicine</i> , 2022, 11, 3024.	1.0	11
306	The Role of Heparin in COVID-19: An Update after Two Years of Pandemics. <i>Journal of Clinical Medicine</i> , 2022, 11, 3099.	1.0	13
307	Therapeutic Trends of Cerebrovascular Disease during the COVID-19 Pandemic and Future Perspectives. <i>Journal of Stroke</i> , 2022, 24, 179-188.	1.4	12
308	To escalate thromboprophylactic heparin intensity in COVID-19 or not? That is still the question. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12738.	1.0	2
309	Safety and Efficacy Analysis of Apixaban Compared to Heparins in Hospitalized Non-Critically Ill COVID-19 Patients. <i>Hospital Pharmacy</i> , 2022, 57, 727-733.	0.4	3
310	Antithrombotic agents in patients with COVID-19. <i>Cmaj</i> , 2022, 194, E704-E704.	0.9	1
311	SARS-CoV-2 RNA copy number is a factor associated with the mortality of COVID-19 and improves the predictive performance of mortality in severe cases.. <i>Japanese Journal of Infectious Diseases</i> , 2022, , .	0.5	0
312	Anticoagulation in hospitalized patients with COVID-19. <i>Blood</i> , 2022, 140, 809-814.	0.6	12
313	Thrombotic events in critically ill children with coronavirus disease 2019 or multisystem inflammatory syndrome in children. <i>Current Opinion in Pediatrics</i> , 2022, 34, 261-267.	1.0	4

#	ARTICLE	IF	CITATIONS
314	A systems biology approach identifies candidate drugs to reduce mortality in severely ill patients with COVID-19. <i>Science Advances</i> , 2022, 8, .	4.7	14
315	Therapeutic anticoagulation using heparin in early phase severe coronavirus disease 2019: A retrospective study. <i>American Journal of Emergency Medicine</i> , 2022, 58, 84-88.	0.7	0
316	Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211038.	0.7	4
317	Heparin-Induced Thrombocytopenia in COVID-19. , 2022, 19, .		0
318	Management of Acute Respiratory Distress Syndrome in COVID-19 Patients. <i>Acta Anaesthesiologica Belgica</i> , 2022, 73, 5-14.	0.0	0
319	An adaptive platform trial for evaluating treatments in patients with life-threatening hemorrhage from traumatic injuries: Rationale and proposal. <i>Transfusion</i> , 2022, 62, .	0.8	2
320	Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. <i>Lancet Respiratory Medicine</i> , 2022, 10, 700-714.	5.2	22
321	New Insights into Clinical and Mechanistic Heterogeneity of the Acute Respiratory Distress Syndrome: Summary of the Aspen Lung Conference 2021. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 67, 284-308.	1.4	9
322	COVID-19 and Thrombosis: Pathophysiological Mechanisms and Therapeutic Update. , 0, , .		1
323	Role of anticoagulation in lowering the mortality in hospitalized covid-19 patients. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2022, 43, 541-550.	0.5	0
324	Annals for Hospitalists Inpatient Notes - Venous Thromboembolism Prophylaxis in COVID-19: Making Sense of the Evidence. <i>Annals of Internal Medicine</i> , 2022, 175, HO2-HO3.	2.0	1
325	An adaptive platform trial for evaluating treatments in patients with life-threatening hemorrhage from traumatic injuries: Ethical and regulatory considerations. <i>Transfusion</i> , 2022, 62, .	0.8	2
326	An adaptive platform trial for evaluating treatments in patients with life-threatening hemorrhage from traumatic injuries: Planning and execution. <i>Transfusion</i> , 2022, 62, .	0.8	2
327	Special Issue on "Disseminated Intravascular Coagulation: Current Understanding and Future Perspectives". <i>Journal of Clinical Medicine</i> , 2022, 11, 3315.	1.0	0
328	Effect of intermediate/high versus low dose heparin on the thromboembolic and hemorrhagic risk of unvaccinated COVID-19 patients in the emergency department. <i>BMC Emergency Medicine</i> , 2022, 22, .	0.7	0
329	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19. <i>Journal of the American College of Cardiology</i> , 2022, , .	1.2	7
330	Effect of heparin treatment on pulmonary embolism and in-hospital death in unvaccinated COVID-19 patients without overt deep vein thrombosis. <i>Thrombosis Journal</i> , 2022, 20, .	0.9	1
331	Full Characterization of Thrombotic Events in All Hospitalized COVID-19 Patients in a Spanish Tertiary Hospital during the First 18 Months of the Pandemic. <i>Journal of Clinical Medicine</i> , 2022, 11, 3443.	1.0	5

#	ARTICLE	IF	CITATIONS
332	COVID-19 coagulopathy – what should we treat?. <i>Experimental Physiology</i> , 2022, 107, 749-758.	0.9	8
333	Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2022, 10, 1128-1136.	0.9	4
334	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 0, .	0.9	5
335	Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID-19: A Propensity Score-Matched Cohort Analysis of the HOPE-COVID-19 Registry. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	8
336	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. <i>Blood Advances</i> , 2022, 6, 4975-4982.	2.5	21
337	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2022, 60, 2200803.	3.1	22
338	Efficacy and Safety of Intensified Versus Standard Prophylactic Anticoagulation Therapy in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	4
339	Pharmacological Studies in Hospitalized COVID-19 Patients in Belgium: We Could Do Better. <i>Viruses</i> , 2022, 14, 1427.	1.5	1
340	Thromboelastometry Predicts Thromboembolic Events, Hospital Length of Stay, and Mortality in Patients with COVID-19 Infection and Mild Hypoxemia: A Prospective Observational Study. <i>Journal of Blood Medicine</i> , 0, Volume 13, 363-372.	0.7	1
341	Clinical applications of machine learning in the survival prediction and classification of sepsis: coagulation and heparin usage matter. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
342	Management of Cardiovascular Disease in Patients With COVID-19 and Chronic Chagas Disease: Implications to Prevent a Scourge Still Larger. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
343	Differences in clinical features and mortality in very old unvaccinated patients (≥80 years) hospitalized with COVID-19 during the first and successive waves from the multicenter SEMI-COVID-19 Registry (Spain). <i>BMC Geriatrics</i> , 2022, 22, .	1.1	6
344	High-dose versus low-dose venous thromboprophylaxis in hospitalized patients with COVID-19: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , 2022, 17, 1817-1825.	1.0	8
345	Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19. <i>Blood Advances</i> , 2022, 6, 4710-4714.	2.5	5
346	Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. <i>Lancet Haematology</i> , the, 2022, 9, e594-e604.	2.2	38
347	The Impact of Key Secular Trends During the first Three Waves the COVID-19 Pandemic. <i>Annals of Epidemiology</i> , 2022, , .	0.9	2
348	Upcoming and urgent challenges in critical care research based on COVID-19 pandemic experience. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, , 101121.	0.6	2
349	Efficacy and safety of hyperbaric oxygen treatment to treat COVID-19 pneumonia: a living systematic review update. <i>Diving and Hyperbaric Medicine</i> , 2022, 52, 126-135.	0.2	2

#	ARTICLE	IF	CITATIONS
350	Current Effective Therapeutics in Management of COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 3838.	1.0	23
351	The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2022, 43, 715-722.	0.5	1
352	COVID-19 increases the risk for the onset of atrial fibrillation in hospitalized patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	25
354	ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	1.9	100
355	Thromboprophylaxis in people hospitalized with COVID-19: Assessing intermediate or standard doses in a retrospective cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	0
356	Clinical Characteristics and Treatment Outcomes of COVID-19 Patients at Eka Kotebe General Hospital, Addis Ababa, Ethiopia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 107, 252-259.	0.6	1
357	Dynamics of disease characteristics and clinical management of critically ill COVID-19 patients over the time course of the pandemic: an analysis of the prospective, international, multicentre RISC-19-ICU registry. <i>Critical Care</i> , 2022, 26, .	2.5	11
358	Thromboprophylaxis Strategies for Hospitalized Patients With COVID-19. <i>Chest</i> , 2022, 162, e69-e70.	0.4	1
359	Association Between the Development of Thrombosis and Worsening of Disease Severity in Patients With Moderate COVID-19 on Admission From the CLOT-COVID Study. <i>Circulation Journal</i> , 2023, 87, 448-455.	0.7	3
360	Venous Thromboembolism in Sepsis: From Bench to Bedside. <i>Biomedicines</i> , 2022, 10, 1651.	1.4	5
361	Coronavirus Disease 2019-Related Extensive Thrombosis in a Patient Receiving Therapeutic Anticoagulation With Dabigatran. <i>Hospital Pharmacy</i> , 0, , 001857872211087.	0.4	1
362	Antiphospholipid antibodies and vitamin D deficiency in COVID-19 infection with and without venous or arterial thrombosis: A pilot case-control study. <i>PLoS ONE</i> , 2022, 17, e0269466.	1.1	3
363	Heparin Resistance in SARS-CoV-2 Infected Patients with Venous Thromboembolism. <i>Hospital Pharmacy</i> , 0, , 001857872211117.	0.4	1
364	Bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study. <i>Intensive Care Medicine</i> , 2022, 48, 1039-1052.	3.9	33
365	Heart failure in general and cardiac transplant patients with COVID-19. <i>World Journal of Cardiology</i> , 2022, 14, 392-402.	0.5	0
366	Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations—State-of-the-Art. <i>Anticancer Research</i> , 2022, 42, 3261-3274.	0.5	5
367	3D-PAST: Risk Assessment Model for Predicting Venous Thromboembolism in COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 3949.	1.0	2
368	Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12747.	1.0	4

#	ARTICLE	IF	CITATIONS
369	Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2226-2236.	1.9	23
370	Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis. <i>BMJ, The</i> , 0, , e070022.	3.0	7
371	A Prospective Study Evaluating Cumulative Incidence and a Specific Prediction Rule in Pulmonary Embolism in COVID-19. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	8
372	The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges. <i>Thrombosis Update</i> , 2022, 8, 100117.	0.4	1
373	Outcomes of COVID-19 in a Large Cohort of Lung Transplant Recipients: A Retrospective Study. <i>Transplantation</i> , 2022, 3, 257-266.	0.3	1
374	Bleeding and thrombotic complications in patients with severe COVID-19: A prospective observational study. <i>Health Science Reports</i> , 2022, 5, .	0.6	3
375	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197.	1.8	46
376	Beta receptor blocker therapy for the elderly in the COVID-19 era. <i>World Journal of Clinical Cases</i> , 2022, 10, 8088-8096.	0.3	2
377	Adoption and Deadoption of Medications to Treat Hospitalized Patients With COVID-19. , 2022, 4, e0727.		3
378	Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	9
379	Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients. <i>European Respiratory Journal</i> , 2022, 60, 2200780.	3.1	15
380	Therapeutic Approaches to the Neurologic Manifestations of COVID-19. <i>Neurotherapeutics</i> , 2022, 19, 1435-1466.	2.1	22
381	Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	6
382	Patients with myeloproliferative neoplasms and COVID-19 have increased rates of arterial thrombosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12752.	1.0	3
383	Biomarker derived risk scores predict venous thromboembolism and major bleeding among patients with COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	1
384	Treatment of COVID-19 Pneumonia and Acute Respiratory Distress With Ramatroban, a Thromboxane A2 and Prostaglandin D2 Receptor Antagonist: A Four-Patient Case Series Report. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
385	Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2023, 29, 13-21.	2.8	19
386	Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework. <i>Journal of Clinical Medicine</i> , 2022, 11, 4464.	1.0	13

#	ARTICLE	IF	CITATIONS
387	Thromboprophylaxis for children hospitalized with COVID-19 and MISâ€œ. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	1.0	6
388	Does high-dose thromboprophylaxis improve outcomes in COVID-19 patients? A meta-analysis of comparative studies. TH Open, 0, , .	0.7	1
389	Coagulopathy in COVID-19 and anticoagulation clinical trials. Best Practice and Research in Clinical Haematology, 2022, 35, 101377.	0.7	3
390	Cardiovascular Complications of Pregnancy-Associated COVID-19 Infections. , 2022, 1, 100057.		6
391	Ability of IMPROVE and IMPROVE-DD scores to predict outcomes in patients with severe COVID-19: a prospective observational study. Scientific Reports, 2022, 12, .	1.6	1
392	Otolaryngology consultations for COVID-19 patients: A retrospective cohort study of indications, interventions, and considerations. Auris Nasus Larynx, 2022, , .	0.5	0
393	Empiric Anticoagulation Therapy in Hospitalized COVID-19 Patients: An Evaluation of Bleeding Risk Scores Performances in Predicting Bleeding Events. Journal of Clinical Medicine, 2022, 11, 4965.	1.0	2
394	Preadmission Oral Anticoagulation for Atrial Fibrillation/Flutter and Death or Thrombotic Events During COVID-19 Admission. American Journal of Cardiology, 2022, 181, 38-44.	0.7	3
395	Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis. Thrombosis Journal, 2022, 20, .	0.9	3
396	The pharmacology of anticoagulant drug treatment options in COVID-19 patients: reviewing real-world evidence in clinical practice. Expert Review of Clinical Pharmacology, 2022, 15, 1095-1105.	1.3	2
397	Incidence of thromboembolic complications in hospitalized COVID-19 patients in a medical ward in Japan: A single-center retrospective and prospective observational study. Medicine (United States), 2022, 101, e29933.	0.4	0
399	Care of the Seriously Ill Patient with SARS CoV-2. Medical Clinics of North America, 2022, , .	1.1	1
400	Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. Journal of Clinical Investigation, 2022, 132, .	3.9	76
401	A comparison of three thromboprophylaxis regimens in critically ill COVID-19 patients: An analysis of real-world data. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
402	Antithrombotiques chez les patients atteints de COVID-19. Cmaj, 2022, 194, E1074-E1075.	0.9	0
403	Coronavirus Disease 2019-Associated Coagulopathy. Microorganisms, 2022, 10, 1556.	1.6	8
404	Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19. Microorganisms, 2022, 10, 1639.	1.6	5
405	Deep Learningâ€œBased Time-to-Death Prediction Model for COVID-19 Patients Using Clinical Data and Chest Radiographs. Journal of Digital Imaging, 2023, 36, 178-188.	1.6	6

#	ARTICLE	IF	CITATIONS
406	Low molecular weight heparin is associated with better outcomes than unfractionated heparin for thromboprophylaxis in hospitalized COVID-19 patients: a meta-analysis. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 0, , .	1.8	1
407	The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	5
408	Thromboprophylaxis with standard-dose vs. flexible-dose heparin for hospitalized COVID-19 patients: a target trial emulation. <i>Journal of Clinical Epidemiology</i> , 2022, 151, 96-103.	2.4	5
409	Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2022, 7, 60-62.	0.5	0
410	Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients. <i>International Journal of Hematology</i> , 2022, 116, 937-946.	0.7	11
411	Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 420-430.	1.0	17
412	Supportive Care in Patients with Critical COVID-19. <i>Infectious Disease Clinics of North America</i> , 2022, , .	1.9	0
413	Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19). <i>Journal of Intensive Medicine</i> , 2022, 2, 199-222.	0.8	3
414	A systematic review of biomarkers among hospitalized patients with COVID-19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	3
415	Novel Strategies for the Treatment of COVID-19. <i>Drugs in R and D</i> , 2022, 22, 257-262.	1.1	5
416	Pulmonary embolism in a patient with eltrombopag-treated aplastic anaemia and paroxysmal nocturnal haemoglobinuria clone during COVID-19 pneumonia. <i>Thrombosis Journal</i> , 2022, 20, .	0.9	7
417	Diffuse alveolar damage patterns reflect the immunological and molecular heterogeneity in fatal COVID-19. <i>EBioMedicine</i> , 2022, 83, 104229.	2.7	13
418	Venous Thromboembolic Disease in COVID-19, Pathophysiology, Therapy and Prophylaxis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10372.	1.8	3
419	Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records. <i>TH Open</i> , 2022, 06, e408-e420.	0.7	5
421	Clinical, laboratory and immunohistochemical characterization of in situ pulmonary arterial thrombosis in fatal COVID-19. <i>Thrombosis Research</i> , 2022, 219, 95-101.	0.8	5
422	Anticoagulation in COVID-19 patients – An updated systematic review and meta-analysis. <i>Thrombosis Research</i> , 2022, 219, 40-48.	0.8	12
423	Effect of combining anticoagulant and glucocorticoid therapy on mortality in patients with severe COVID-19. <i>European Journal of Inflammation</i> , 2022, 20, 1721727X2211009.	0.2	0
424	Early prophylactic anticoagulation with heparin alleviates mortality in critically ill patients with sepsis: a retrospective analysis from the MIMIC-IV database. <i>Burns and Trauma</i> , 2022, 10, .	2.3	7

#	ARTICLE	IF	CITATIONS
425	Letter to the Editor: Venous Thromboembolism in COVID-19: Are Women Different?. Indian Journal of Cardiovascular Disease in Women WINCARS, 0, 07, 007-008.	0.1	0
426	Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211163.	0.7	2
427	The diverse role of heparan sulfate and other GAGs in SARS-CoV-2 infections and therapeutics. Carbohydrate Polymers, 2023, 299, 120167.	5.1	8
428	Strategies for Cardio-Oncology Care During the COVID-19 Pandemic. Current Treatment Options in Cardiovascular Medicine, 2022, 24, 137-153.	0.4	2
429	Use of anticoagulants in patients with COVID-19: a living systematic review and meta-analysis. Jornal Brasileiro De Pneumologia, 0, , e20220041.	0.4	3
430	Standardization of D-dimer reporting in the COVID-19 era. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	1.0	1
431	Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT. Circulation, 2022, 146, 1344-1356.	1.6	39
432	Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection. Herald of the Russian Academy of Sciences, 2022, 92, 430-436.	0.2	0
433	A novel anticoagulation treatment protocol using unfractionated heparin for coronavirus disease 2019 patients in Japan, 2022. Global Health & Medicine, 2022, 4, 233-236.	0.6	1
434	Rotational thromboelastometry in critically ill COVID-19 patients does not predict thrombosis. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12798.	1.0	3
435	COVID-19: Opportunities to Improve Prognosis. Herald of the Russian Academy of Sciences, 2022, 92, 404-411.	0.2	1
436	Anticoagulation Strategies during Extracorporeal Membrane Oxygenation: A Narrative Review. Journal of Clinical Medicine, 2022, 11, 5147.	1.0	28
437	Thrombosis after SARS-CoV2 infection or COVID-19 vaccination: will a nonpathologic anti-PF4 antibody be a solution? A narrative review. Journal of Bio-X Research, 2022, 5, 97-103.	0.3	1
438	COVID-19-Related ARDS: Key Mechanistic Features and Treatments. Journal of Clinical Medicine, 2022, 11, 4896.	1.0	15
439	Is It Time to Revisit Remdesivir Use for Severe COVID-19?. Indian Journal of Critical Care Medicine, 2022, 26, 983-984.	0.3	2
440	Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial. Intensive Care Medicine, 2022, 48, 1525-1538.	3.9	13
441	Intrapulmonary shunt and alveolar dead space in a cohort of patients with acute COVID-19 pneumonitis and early recovery. European Respiratory Journal, 2023, 61, 2201117.	3.1	8
442	Approach to Thromboprophylaxis for Prevention of Venous Thromboembolism in COVID-19: Global Updates and Clinical Insights from India. Clinics and Practice, 2022, 12, 766-781.	0.6	2

#	ARTICLE	IF	CITATIONS
443	Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 5632.	1.0	5
444	Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	2
445	Which are the optimal thromboprophylaxis strategies for hospitalized patients with COVID-19? current controversies. <i>Vascular</i> , 2024, 32, 220-225.	0.4	0
446	Correlating drug prescriptions with prognosis in severe COVID-19: first step towards resource management. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, .	1.5	1
447	The Case for Therapeutic-Intensity Anticoagulation in Patients with COVID-19-Associated Moderate Illness. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 076-078.	1.5	4
448	Traumatic brain injury: progress and challenges in prevention, clinical care, and research. <i>Lancet Neurology</i> , The, 2022, 21, 1004-1060.	4.9	197
449	Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. <i>Health Research Policy and Systems</i> , 2022, 20, .	1.1	5
450	Higher Dose Anticoagulation Cannot Prevent Disease Progression in COVID-19 Patients: A Systematic Review and Meta-Analysis. <i>Biomedicines</i> , 2022, 10, 2194.	1.4	0
451	Development and Implementation of the National Heart, Lung, and Blood Institute COVID-19 Common Data Elements. <i>Journal of Clinical and Translational Science</i> , 0, , 1-25.	0.3	0
452	Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas. <i>ESC Heart Failure</i> , 2022, 9, 3713-3736.	1.4	12
453	AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021-2022. <i>Jammi</i> , 2022, 7, 163-169.	0.3	0
454	Use of low molecular weight heparin and hemoglobin fall in COVID-19 patients: A STROBE-compliant study. <i>Medicine (United States)</i> , 2022, 101, e30367.	0.4	0
455	Life-threatening retroperitoneal bleeding in coronavirus disease 2019 patient while on full dose anticoagulation: A case report. <i>International Journal of Case Reports and Images</i> , 2022, 13, 86-90.	0.0	0
456	Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID-19 pneumonia. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
458	Respiratory Comorbidity and Pulmonary Embolism. <i>Archivos De Bronconeumologia</i> , 2023, 59, 131-133.	0.4	1
459	C-reactive protein, immunothrombosis and venous thromboembolism. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	21
460	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 995-1015.	1.9	4
461	COVID-19 outcomes in sickle cell disease and sickle cell trait. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101382.	0.7	1

#	ARTICLE	IF	CITATIONS
462	Predictors of fatal neurological complications among admitted COVID-19 patients with their implication in outcome: A Case Control study. PLoS ONE, 2022, 17, e0274485.	1.1	1
463	COVID-19 Thrombotic Complications and Therapeutic Strategies. Annual Review of Medicine, 2023, 74, 15-30.	5.0	4
464	Pulmonary Vascular Thrombosis in COVID-19: Clinical and Morphological Parallels. Rational Pharmacotherapy in Cardiology, 2022, 18, 376-384.	0.3	3
465	Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials. Frontiers in Medicine, 0, 9, .	1.2	10
466	The optimal anticoagulation strategy for COVID-19, prophylactic or therapeutic?: a meta-analysis, trial sequential analysis, and meta-regression of more than 27,000 participants. , 2022, 2, 148-166.		0
467	Incidence, risk factors, and clinical impact of major bleeding in hospitalized patients with COVID-19: a sub-analysis of the CLOT-COVID Study. Thrombosis Journal, 2022, 20, .	0.9	7
468	Care for adults with <scp>COVID</scp> â€19: living guidelines from the National <scp>COVID</scp> â€19 Clinical Evidence Taskforce. Medical Journal of Australia, 2022, 217, 368-378.	0.8	8
469	Prevalence of Venous Thromboembolism and Anticoagulant Use in Patients with COVID-19 in Alberta, Canada. Canadian Journal of Hospital Pharmacy, 2022, 75, 286-293.	0.1	0
470	Knowledge Gaps for Prophylactic Use of Antithrombotic Agents in Patients with COVID-19: Insights into New SARS-CoV-2 Variants, Vaccination Status, and Emerging Oral Antivirals. Thrombosis and Haemostasis, 2023, 123, 186-191.	1.8	4
471	Current practices in pediatric hospitalâ€acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	1.0	0
473	The Comparison of Therapeutic With Prophylactic Anticoagulation on Mortality, Risk of Bleeding, and Thromboembolism in Hospitalized Patients With COVID-19: A Systematic Review. Cureus, 2022, , .	0.2	1
474	In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211318.	0.7	1
475	Japanese rapid/living recommendations on drug management for <scp>COVID</scp> â€19: updated guidelines (July 2022). Acute Medicine & Surgery, 2022, 9, .	0.5	6
476	Tissue plasminogen activator resistance is an early predictor of posttraumatic venous thromboembolism: A prospective study from the CLOTT research group. Journal of Trauma and Acute Care Surgery, 2022, 93, 597-603.	1.1	9
477	â€æ <scp>ISTH</scp> guidelines for antithrombotic treatment in COVIDâ€19â€ Reply. Journal of Thrombosis and Haemostasis, 2022, 20, 2710-2711.	1.9	3
478	Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury. Scientific Reports, 2022, 12, .	1.6	0
479	Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19. Frontiers in Immunology, 0, 13, .	2.2	5
480	From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?. Biomedicines, 2022, 10, 2620.	1.4	6

#	ARTICLE	IF	CITATIONS
481	Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 1169-1177.	5.2	14
482	Venous thromboembolism in critically ill patients with pneumonia in the COVID-19 era: Data from a large public database. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	0
483	Clinical Differences and Outcomes of COVID-19 Associated Pulmonary Thromboembolism in Comparison with Non-COVID-19 Pulmonary Thromboembolism. <i>Journal of Clinical Medicine</i> , 2022, 11, 6011.	1.0	2
484	Incidence of Venous Thromboembolism in Hospitalized COVID-19 Patients Receiving Thromboprophylaxis. <i>Journal of Hematology (Brossard, Quebec)</i> , 2022, 11, 167-175.	0.4	0
485	Investigation of the pharmacokinetic properties of synthetic heparan sulfate oligosaccharides. <i>Glycobiology</i> , 0, , .	1.3	1
486	Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry. <i>Medicina Clínica (English Edition)</i> , 2022, 159, 457-464.	0.1	0
487	Pharmacologic therapies of ARDS: From natural herb to nanomedicine. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
488	Subgroup analyses in venous thromboembolism trials reporting pharmacological interventions: A systematic review. <i>Thrombosis Research</i> , 2023, 232, 151-159.	0.8	1
489	COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 816-832.	1.5	12
490	Inflammatory and Hemostatic Markers in COVID-19 Patients with Arterial Thrombosis Are Significantly Lower at Hospital Admission than in COVID-19 Patients without Thrombosis. <i>Viruses</i> , 2022, 14, 2330.	1.5	0
491	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
492	Therapeutic advances in COVID-19. <i>Nature Reviews Nephrology</i> , 2023, 19, 38-52.	4.1	67
493	Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials. <i>Journal of Clinical Medicine</i> , 2022, 11, 5997.	1.0	13
494	Bivalirudin vs. Enoxaparin in Intubated COVID-19 Patients: A Pilot Multicenter Randomized Controlled Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 5992.	1.0	2
495	Step up to the platelet: Role of platelets in inflammation and infection. <i>Thrombosis Research</i> , 2023, 231, 182-194.	0.8	6
496	Association between Thrombin Generation and Clinical Characteristics in COVID-19 Patients. <i>Acta Haematologica</i> , 2023, 146, 151-160.	0.7	0
497	COVID-19 Therapeutics and Considerations for Pregnancy. <i>Obstetrics and Gynecology Clinics of North America</i> , 2022, , .	0.7	0
499	Thromboembolic and bleeding events in ICU patients with COVID-19: a nationwide, observational study. <i>Acta Anaesthesiologica Scandinavica</i> , 0, , .	0.7	3

#	ARTICLE	IF	CITATIONS
500	Modulation of thromboinflammation in hospitalized COVID-19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWN-ANTICO study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12826.	1.0	2
501	Evaluation of a fast and frugal clinical decision algorithm (â€˜pathwaysâ€™™) on clinical outcomes in hospitalised patients with COVID-19 treated with anticoagulants. <i>Journal of Evaluation in Clinical Practice</i> , 2023, 29, 3-12.	0.9	3
502	Indian Society of Critical Care Medicine Consensus Statement for Prevention of Venous Thromboembolism in the Critical Care Unit. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, S51-S65.	0.3	0
503	Evaluating Risk: Benefit Ratio of Fat-Soluble Vitamin Supplementation to SARS-CoV-2-Infected Autoimmune and Cancer Patients: Do Vitamin-Drug Interactions Exist?. <i>Life</i> , 2022, 12, 1654.	1.1	1
504	Machine Learning Approaches for Phenotyping in Cardiogenic Shock and Critical Illness. , 2022, 1, 100126.		8
505	Assessment of Healthcare Resource Utilization by Anticoagulant Heparinoid Dosage Level in Patients Hospitalized with COVID-19. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211378.	0.7	0
506	Prevalence and Risk Factors of Venous Thromboembolism in Critically Ill Patients with Severe COVID-19 and the Association between the Dose of Anticoagulants and Outcomes. <i>The Journal of Critical Care Medicine</i> , 2022, 8, 249-258.	0.3	0
509	COVID-19 in Russia: Evolution of Views on the Pandemic. Report II. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2022, 77, 291-306.	0.2	2
510	Intensity of anticoagulant dosing in hospitalized patients with COVID-19: an observational, comparative effectiveness study. <i>Journal of Hospital Medicine</i> , 0, , .	0.7	1
511	Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients. <i>Medicina (Lithuania)</i> , 2022, 58, 1649.	0.8	0
512	Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19. <i>Thrombosis Update</i> , 2022, , 100126.	0.4	0
513	Lung Transplantation for COVID-19 patients and COVID-19 in Lung Transplant Recipients. <i>Clinics in Chest Medicine</i> , 2022, , .	0.8	0
514	Pathophysiological mechanisms of thrombosis in acute and long COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
515	Life stressors significantly impact long-term outcomes and post-acute symptoms 12-months after COVID-19 hospitalization. <i>Journal of the Neurological Sciences</i> , 2022, 443, 120487.	0.3	13
516	Promising Drug Fondaparinux for the Treatment of COVID-19: an In Silico Analysis of Low Molecular Weight Heparin, Direct Oral Anticoagulant, and Antiplatelet Drug Interactions with Host Protease Furin. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	1.3	1
517	Characteristics of subarachnoid hemorrhage associated with COVID-19 infection: A systematic review and descriptive analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2023, 32, 106904.	0.7	1
518	COVID-19 signalome: Potential therapeutic interventions. <i>Cellular Signalling</i> , 2023, 103, 110559.	1.7	5
519	COVID-19 pandemic: the impact on Canada's™ intensive care units. <i>Facets</i> , 2022, 7, 1411-1472.	1.1	3

#	ARTICLE	IF	CITATIONS
520	COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE RISK OF THROMBOEMBOLIC EVENTS AND CURRENT OPTIONS FOR ANTITHROMBOTIC PROPHYLAXIS. , 2022, , 88-103.	0.3	0
521	Practice of Awake Prone Positioning in Critically Ill COVID-19 Patientsâ€”Insights from the PRoAcTâ€”COVID Study. Journal of Clinical Medicine, 2022, 11, 6988.	1.0	2
522	Characteristics and Outcomes of Critically Ill Pregnant/Postpartum Women with COVID-19 Pneumonia in Western Balkans, The Republic of Srpska Report. Medicina (Lithuania), 2022, 58, 1730.	0.8	2
523	COVID-19 and Pulmonary Thrombosisâ€”An Unresolved Clinical Puzzle: A Single-Center Cohort Study. Journal of Clinical Medicine, 2022, 11, 7049.	1.0	3
524	Impact of COVID-19 on Non-Pulmonary Critical Illness: Prevalence, Clinical Manifestations, Management, and Outcomes. Clinics in Chest Medicine, 2022, , .	0.8	0
525	Hypercoagulability in critically ill patients with COVID 19, an observational prospective study. PLoS ONE, 2022, 17, e0277544.	1.1	5
526	Pathophysiology of Hypoxemia in COVID-19 Lung Disease. Clinics in Chest Medicine, 2023, 44, 239-248.	0.8	3
527	Challenges in evaluating treatments for COVID-19: The case of in-hospital anticoagulant use and the risk of adverse outcomes. Frontiers in Pharmacology, 0, 13, .	1.6	0
528	Platform trials for anaesthesia and perioperative medicine: a narrative review. British Journal of Anaesthesia, 2023, 130, 677-686.	1.5	3
530	How to use and report data on Dâ€dimer testing in the <scp>COVID</scp> â€19 era?. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	1.0	0
531	Pathological Lung Patterns of COVID-19 and its Clinical Correlation to Disease Severity. Indian Journal of Critical Care Medicine, 2022, 26, 1285-1292.	0.3	2
532	Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. Annals of Internal Medicine, 2022, 175, 1716-1727.	2.0	2
533	Treatment of pregnant and early postpartum women with severe and critical COVID-19: experience at a tertiary center. European Journal of Medical Research, 2022, 27, .	0.9	1
535	The Effectiveness of the Intermediate and Therapeutic Doses of Enoxaparin in COVID-19 Patients: A Comparative Study of Factor Xa Inhibition. Acta Haematologica, 2023, 146, 137-143.	0.7	0
536	The Histone Methyltransferase MLL1/KMT2A in Monocytes Drives Coronavirus-Associated Coagulopathy and Inflammation. Blood, 0, , .	0.6	2
537	A leap towards personalised therapy of acute lung injury. European Respiratory Journal, 2022, 60, 2201808.	3.1	1
538	Changes in anticoagulant and antiplatelet drug supply at US hospitals before and during the COVID-19 pandemic (2018-2021). American Journal of Health-System Pharmacy, 0, , .	0.5	0
539	Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 2023, 329, 39.	3.8	64

#	ARTICLE	IF	CITATIONS
540	Safety and efficacy of prophylactic anticoagulation versus therapeutic anticoagulation in hospitalized COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Respiratory Journal</i> , 2023, 17, 73-79.	0.6	3
541	ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial. <i>Trials</i> , 2022, 23, .	0.7	4
543	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. <i>European Journal of Cancer</i> , 2023, 181, 102-118.	1.3	2
544	COVID-19 and Pulmonary Embolism Outcomes among Hospitalized Patients in the United States: A Propensity-Matched Analysis of National Inpatient Sample. <i>Vaccines</i> , 2022, 10, 2104.	2.1	4
545	Identification of two specific transcriptomic clusters of COVID-19 ARDS patients with different immune profiles and different outcomes. <i>European Respiratory Journal</i> , 0, , 2202008.	3.1	0
547	COVID-19 drug-induced liver injury: A recent update of the literature. <i>World Journal of Gastroenterology</i> , 0, 28, 6314-6327.	1.4	5
548	Thrombosis questions from the inpatient wards. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 481-490.	0.9	1
549	Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 1617-1628.	1.1	3
550	Anticoagulation Strategies in Non-Critically Ill Patients with Covid-19. , 2023, 2, .		5
551	To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 506-514.	0.9	4
552	Gaps and opportunities in sepsis translational research. <i>EBioMedicine</i> , 2022, 86, 104387.	2.7	6
553	Long-term Follow-up After Critical COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 0, , .	3.8	4
554	Major Publications in the Critical Care Pharmacotherapy Literature: 2021. , 2022, 4, e0823.		1
555	Downregulation of the Protein C Signaling System Is Associated with COVID-19 Hypercoagulability—A Single-Cell Transcriptomics Analysis. <i>Viruses</i> , 2022, 14, 2753.	1.5	3
556	Post-discharge Thromboembolic Events in COVID-19 Patients: A Review on the Necessity for Prophylaxis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2023, 29, 107602962211484.	0.7	5
557	Effect of a systematic lung-protective protocol for COVID-19 pneumonia requiring invasive ventilation: A single center retrospective study. <i>PLoS ONE</i> , 2023, 18, e0267339.	1.1	0
558	Pulmonary Embolism After COVID-19 (Epidemiology, Influence on Prognosis, Pathogenesis, Treatment). <i>Contemporary Cardiology</i> , 2022, , 243-254.	0.0	0
559	Multi-marker risk assessment in patients hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>American Heart Journal</i> , 2023, 258, 149-156.	1.2	3

#	ARTICLE	IF	CITATIONS
560	Microvascular significance of TGF- β 2 axis activation in COVID-19. <i>Frontiers in Cardiovascular Medicine</i> , 2023, 9, .	1.1	11
561	Risk Factors and Impact on Outcomes of Thrombosis in Patients with COVID-19 in Japan: From the CLOT-COVID Study. <i>Annals of Vascular Diseases</i> , 2023, .	0.2	0
562	Models for Evidence Generation During the COVID-19 Pandemic: New Opportunities for Clinical Trials in Cardiovascular Medicine. <i>Circulation</i> , 2023, 147, 187-189.	1.6	4
563	A Review of Coronavirus Disease 2019 in Pregnancy. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 050-065.	0.8	0
564	Reply to Bareille et al. Are Viscoelastometric Assays of Old Generation Ready for Disposal? Comment on Volod et al. Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. <i>J. Clin. Med.</i> 2022, 11, 860. <i>Journal of Clinical Medicine</i> , 2023, 12, 478.	1.0	1
565	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities. <i>PLoS Pathogens</i> , 2023, 19, e1011063.	2.1	7
566	Predictive Value of Echocardiographic Pulmonary to Left Atrial Ratio for In-Hospital Death in Patients with COVID-19. <i>Diagnostics</i> , 2023, 13, 224.	1.3	0
567	Perspective Chapter: Cardiovascular Post-Acute COVID-19 Syndrome – Definition, Clinical Scenarios, Diagnosis, and Management. , 0, , .		1
569	Efficacy and safety of two heparin regimens for prevention of venous thromboembolism in hospitalized patients with COVID-19: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2023, 18, 863-877.	1.0	2
570	Omicron, Long-COVID, and the Safety of Elective Surgery for Adults and Children: Joint Guidance from the Therapeutics and Guidelines Committee of the Surgical Infection Society and the Surgery Strategic Clinical Network, Alberta Health Services. <i>Surgical Infections</i> , 2023, 24, 6-18.	0.7	4
571	Acute Mesenteric Ischemia in COVID-19 While Receiving Prophylactic Enoxaparin. <i>Clinical Medicine and Research</i> , 2022, 20, 236-240.	0.4	1
573	Thromboprophylaxis in COVID-19. <i>Medicina Interna (Bucharest, Romania)</i> , 2022, 19, 59-69.	0.1	0
575	Network pharmacology- and molecular simulation-based exploration of therapeutic targets and mechanisms of heparin for the treatment of sepsis/COVID-19. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 12586-12598.	2.0	5
576	Antithrombotic therapy in COVID-19 patients. <i>Obstetrics, Gynecology and Reproduction</i> , 2023, 16, 718-731.	0.2	1
577	Mechanisms of impaired alveolar fluid clearance. <i>Anatomical Record</i> , 0, , .	0.8	2
578	Chronic anti-coagulation therapy reduced mortality in patients with high cardiovascular risk early in COVID-19 pandemic. <i>Thrombosis Journal</i> , 2023, 21, .	0.9	0
579	COVID-19 and atrial fibrillation: Intercepting lines. <i>Frontiers in Cardiovascular Medicine</i> , 2023, 10, .	1.1	11
580	Enoxaparin Posology According to Prothrombotic Status and Bleeding Risk in Hospitalized Patients with SARS-CoV-2 Pneumonia. <i>Journal of Clinical Medicine</i> , 2023, 12, 928.	1.0	0

#	ARTICLE	IF	CITATIONS
581	Electrical Impedance Tomography As a Bedside Diagnostic Tool for Pulmonary Embolism. , 2023, 5, e0843.		3
582	The Conundrum of Anticoagulation for Hospitalized Patients with Covid-19. , 2023, 2, .		0
583	Microvascular Thrombosis as a Critical Factor in Severe COVID-19. International Journal of Molecular Sciences, 2023, 24, 2492.	1.8	10
584	COVID-19 and Cavitory Lesion in Lung. Cureus, 2023, , .	0.2	2
585	Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles. JAMA Network Open, 2023, 6, e2253301.	2.8	0
586	Is perioperative COVID-19 really associated with worse surgical outcomes? A nationwide COVIDSurg propensity-matched analysis. Journal of Trauma and Acute Care Surgery, 2023, 94, 513-524.	1.1	5
587	A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection. PLoS ONE, 2023, 18, e0274243.	1.1	0
588	Distribution of aeration and pulmonary blood volume in healthy, ARDS and COVID-19 lungs: a dual-energy computed tomography retrospective cohort study. Academic Radiology, 2023, , .	1.3	0
589	The Collateral Benefit of COVID Pandemic: Improved Pharmacological Venous Thromboembolism Prophylaxis Practices in Non-COVID Patients. International Journal of General Medicine, 0, Volume 16, 1069-1079.	0.8	0
590	International platform trials: as diseases cross borders, so should trials. Lancet Infectious Diseases, The, 2023, 23, 530-531.	4.6	0
591	Effect of therapeutic anticoagulation on gas exchange in mechanically ventilated COVID-19 patients: A secondary analysis of the COVID-HEP trial. Thrombosis Research, 2023, 224, 13-16.	0.8	0
593	Thromboembolic Events in COVID-19. Contemporary Cardiology, 2022, , 201-216.	0.0	0
594	Thromboembolic events in hospitalised patients with COVID-19: ecological assessment with a scoping review. BMJ Open, 2023, 13, e066218.	0.8	3
595	FEATURES OF COAGULOPATHY AND SYSTEMIC INFLAMMATION IN PATIENTS AFTER COVID-19 INFECTION. WiadomoÅci Lekarskie, 2022, 75, 2907-2914.	0.1	0
596	The Efficacy and Safety of Prolonged Oral Anticoagulation for the Prevention of Thromboembolic Events in Patients Recovered From COVID-19 1 Year After Hospital Discharge: The SARCOV-19 Prospective Registry. Clinical and Applied Thrombosis/Hemostasis, 2023, 29, 107602962311517.	0.7	1
597	Incidence of lower limb deep vein thrombosis in patients with COVID-19 pneumonia through different waves of SARS-CoV-2 pandemic: A multicenter prospective study. PLoS ONE, 2023, 18, e0280247.	1.1	1
598	The Effect of Heparin Full-Dose Anticoagulation on Survival of Hospitalized, Non-critically Ill COVID-19 Patients: A Meta-analysis of High Quality Studies. Lung, 2023, 201, 135-147.	1.4	7
599	The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	17

#	ARTICLE	IF	CITATIONS
600	Therapeutic options in COVID-19. , 2023, , 647-672.		0
601	MICHELLE trial: Inching towards the holy grail of post-discharge anticoagulation in Covid-19!. The National Medical Journal of India, 0, 35, 290-292.	0.1	0
602	Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. BMJ Open, 2023, 13, e067910.	0.8	7
603	Extracardiac Prothrombotic Effects of COVID-19. Heart Failure Clinics, 2023, 19, 213-220.	1.0	0
604	An Emerging Role for Type I Interferons as Critical Regulators of Blood Coagulation. Cells, 2023, 12, 778.	1.8	6
607	Effects of 12Âmg vs. 6Âmg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial. Annals of Intensive Care, 2023, 13, .	2.2	1
608	Hemorrhage, Disseminated Intravascular Coagulopathy, and Thrombosis Complications Among Critically Ill Patients with COVID-19: An International COVID-19 Critical Care Consortium Study*. Critical Care Medicine, 2023, 51, 619-631.	0.4	7
609	Interactions between the reninâ€“angiotensinâ€“aldosterone system and COVID-19. , 2023, , 355-373.		0
610	Retroperitoneal hematoma: An unexpected complication of anticoagulant therapy in COVID-19 patients. Srpski Arhiv Za Celokupno Lekarstvo, 2023, , 23-23.	0.1	0
611	Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital. Frontiers in Immunology, 0, 14, .	2.2	0
612	Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19. Journal of the American College of Cardiology, 2023, 81, 1747-1762.	1.2	24
613	Treating COVID-19: Targeting the Host Response, Not the Virus. Life, 2023, 13, 712.	1.1	2
614	Thrombosis and bleeding in patients with COVID-19 requiring extracorporeal membrane oxygenation: a systematic review and meta-analysis. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100103.	1.0	4
615	Assessing the effects of therapeutic combinations on SARS-CoV-2 infected patient outcomes: A big data approach. PLoS ONE, 2023, 18, e0282587.	1.1	0
617	Novel mechanisms of thrombo-inflammation during infection: spotlight on neutrophil extracellular trap-mediated platelet activation. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100116.	1.0	11
618	Anti-cytokine Therapy in Critical Illness: Is There a Role?. Lessons From the ICU, 2023, , 277-297.	0.1	0
619	Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association. Circulation, 2023, 147, .	1.6	12
620	Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19. JAMA Network Open, 2023, 6, e232338.	2.8	7

#	ARTICLE	IF	CITATIONS
621	The effect of anti-coagulation dosage on the outcome of hospitalized COVID-19 patients in Ethiopia: a multi-center retrospective cohort study. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	0
622	COVID-19 Associated Micro-Anastomotic Thrombosis After Abdominal Free Tissue Transfer: A Case Report and Literature Review. <i>Plastic Surgery</i> , 0, , 229255032311610.	0.4	0
623	Safety and Efficacy of Different Anticoagulant Doses for Patients with COVID-19 in the ICU: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 2222.	1.0	0
624	Retrospective Study of Thrombosis in Hospitalized Patients with COVID-19 in Rural North Carolina. <i>North Carolina Medical Journal</i> , 2023, 84, .	0.1	0
625	Mechanisms of COVID-19 Associated Pulmonary Thrombosis: A Narrative Review. <i>Biomedicines</i> , 2023, 11, 929.	1.4	0
626	Immunothrombosis and COVID-19 â€” a nested post-hoc analysis from a 3186 patient cohort in a Latin American public reference hospital. <i>Clinics</i> , 2023, 78, 100178.	0.6	0
627	Rivaroxabana em Pacientes Ambulatoriais com COVID-19 Leve ou Moderada: FundamentaÃ§Ã£o e Desenho do Estudo CARE (CARE â€” Coalition COVID-19 Brazil VIII). <i>Arquivos Brasileiros De Cardiologia</i> , 2023, 120, .	0.3	1
628	Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1066.	3.8	25
630	Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia. <i>JAMA Internal Medicine</i> , 2023, 183, 520.	2.6	11
631	Anticoagulation in Patients With COVID-19 Pneumoniaâ€”What Is the Optimal Intensity?. <i>JAMA Internal Medicine</i> , 2023, 183, 532.	2.6	3
632	An Evolving Understanding of the Basis and Management of Vascular Complications of COVID-19: Where Do We Go From Here?. <i>Canadian Journal of Cardiology</i> , 2023, 39, 865-874.	0.8	2
633	Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance. <i>Journal of Inflammation</i> , 2023, 20, .	1.5	2
634	Neurologic Complications of Patients With COVID-19 Requiring Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis. , 2023, 5, e0887.		1
635	D-dimer testing: A narrative review. <i>Advances in Clinical Chemistry</i> , 2023, , 151-223.	1.8	1
636	Approaches to Assure Similarity between Pharmaceutical Heparins from Two Different Manufacturers. <i>Pharmaceutics</i> , 2023, 15, 1115.	2.0	2
637	Differences in clinical characteristics and quantitative lung CT features between vaccinated and not vaccinated hospitalized COVID-19 patients in Italy. <i>Annals of Intensive Care</i> , 2023, 13, .	2.2	2
638	Incidence of deep venous thrombosis in COVID-19 critically ill patients treated with intermediate-dose of heparin for thromboprophylaxis: The COVIDOP-DVT observational study. <i>Vascular</i> , 0, , 170853812311650.	0.4	0
639	Longitudinal Trends in Cardiovascular Risk Factor Profiles and Complications Among Patients Hospitalized for COVID-19 Infection: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2023, 16, .	0.9	2

#	ARTICLE	IF	CITATIONS
640	Treatment options for patients with severe COVID-19. <i>Global Health & Medicine</i> , 2023, 5, 99-105.	0.6	1
641	Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1183.	3.8	19
642	Ongoing Uncertainties in Bleeding and Clotting Complications in Patients With COVID-19*. <i>Critical Care Medicine</i> , 2023, 51, 688-691.	0.4	0
643	Dexamethasone Modulates the Cytokine Response but Not COVID-19-Induced Coagulopathy in Critically Ill. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7278.	1.8	4
644	Anticoagulation strategy and safety in critically ill COVID-19 patients: a French retrospective multicentre study. <i>Thrombosis Journal</i> , 2023, 21, .	0.9	0
646	Therapeutic strategies for COVID-19: progress and lessons learned. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 449-475.	21.5	112
657	Case report: Spontaneous hemothorax following anticoagulation for microthrombi in severe COVID pneumonia. <i>Respiratory Medicine Case Reports</i> , 2023, 44, 101864.	0.2	1
658	Continuation of therapeutic dose heparin for critically ill patients with COVID-19. <i>Intensive Care Medicine</i> , 2023, 49, 873-875.	3.9	3
665	COVID-19 and Hematopoietic Stem Cell Transplantation. , 2023, , 177-192.		0
680	Endothelium dysfunction and thrombosis in COVID-19 with type 2 diabetes. <i>Endocrine</i> , 2023, 82, 15-27.	1.1	2
709	Reply to "Embracing imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19" <i>Angiogenesis</i> , 2023, 26, 485-486.	3.7	0
750	COVID-19 und VTE-Prophylaxe. <i>Springer Reference Medizin</i> , 2024, , 1-11.	0.0	0
751	Oral Infections, SARS-CoV-2 Infection, and Autoimmunity. , 2024, , 1013-1044.		0